Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
Eli Lilly blamed the shortfall on lower-than-anticipated demand ... As for its other main weight-loss drug, Zepbound, ...
The company expects Q4 2024 revenue of approximately $13.5 billion. The updated revenue guidance is $400 million lower than ...
Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...
Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback